Regulation of NEMO modifications in radiation-induced NF-kB signaling
辐射诱导的 NF-kB 信号传导中 NEMO 修饰的调节
基本信息
- 批准号:8656285
- 负责人:
- 金额:$ 2.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-08-01 至 2015-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAntineoplastic AgentsApicalApoptoticAttenuatedBindingC-terminalCamptothecinCancer PatientCell DeathCell NucleusCell SurvivalCellsCessation of lifeComplexCouplesDNA DamageDNA Double Strand BreakDataDeath DomainDoxorubicinDrug TargetingEtoposideEvaluationEventGenesGerm-Line MutationGoalsHumanImmunologic ReceptorsIonizing radiationLigaseMalignant NeoplasmsMapsMediatingMethodsModificationMolecularMusMutagensNF-kappa BNFKB Signaling PathwayNuclearPathway interactionsPeptide HydrolasesPharmaceutical PreparationsPhosphotransferasesPhysiologicalPlayPost-Translational Protein ProcessingPublishingRadiationRadiation ToleranceRadioRegulationResearchResistanceRoleSignal PathwaySignal TransductionSignal Transduction PathwaySignaling MoleculeSiteSmall Ubiquitin-Related Modifier ProteinsSpecificityStimulusTestingTissuesUbiquitinVP 16Whole-Body IrradiationZinc Fingersataxia telangiectasia mutated proteinbasecancer cellcancer therapycell behaviorcytokineenzyme mechanismimprovedin vivokillingsmouse modelnovelparalogous geneprotein inhibitors of activated STATresponsetranscription factor
项目摘要
Activation of NF-kB by DNA-damaging anticancer agents, including ionizing radiation (IR), has emerged as an important modulator of malignant cell behaviors, such as resistance to apoptotic cell death. This signal transduction pathway also serves as a paradigm to understand how nuclear DNA damage may induce nucleus-to-cytoplasmic signal transduction pathways. We have previously discovered a novel nucleus-to-cytoplasmic NF-kB signaling pathway induced by IR and other agents that can induce DNA double strand breaks (DSBs). This signaling pathway involves a post-translational modification (PTM) of NEMO (NF-kB essential modulator)/IKK3, the regulatory subunit of the I:B kinase (IKK) complex, by SUMO-1 (small ubiquitin-like modifier 1). We now generated a novel Nemo[DK] knockin mice harboring a germ-line mutation of the sumoylation sites. In the current proposal, we will establish the physiological importance of this new NF-kB signaling pathway in response to IR by directly evaluating the role of NEMO sumoylation in vivo and further dissect the critical upstream and downstream mechanisms. The following three aims will address our central hypothesis that NEMO sumoylation plays a critical physiological role in mediating NF-kB activation by IR to modulate radiation sensitivity in vivo: Aim 1: Determine the roles of NEMO sumoylation in modulating radiation sensitivity in vivo. Aim 2: Reveal the upstream role of NEMO zinc finger in promoting NEMO sumoylation. Aim 3. Elucidate SUMO-1 specific downstream regulation of NEMO function. We believe that the proposed research is important for two major reasons. First, the described research will uncover novel NF-kB signal transduction mechanisms in response to DNA damage stimuli. Second, understanding the mechanisms of NF-kB activation by DNA damaging agents may help identify novel drug targets to improve the current methods of cancer therapy.
核因子-kB被DNA损伤的抗癌剂激活,包括电离辐射(IR),已成为抵抗细胞凋亡等恶性细胞行为的重要调节剂。这一信号转导途径也是理解核DNA损伤如何诱导核-细胞质信号转导途径的范例。我们以前发现了一种新的核质-核转录因子-kB信号通路,它可以诱导DNA双链断裂(DSB)。该信号通路涉及I:B激酶(IKK)复合体的调节亚基NEMO(核因子-kB必需调节物)/IKK3被SUMO-1(小泛素样修饰物1)翻译后修饰。我们现在创造了一种新的Nemo[DK]敲门小鼠,该小鼠含有苏甲基化位点的胚系突变。在目前的方案中,我们将通过直接评估NEMO相扑在体内的作用来确定这一新的NF-kB信号通路在IR反应中的生理重要性,并进一步剖析关键的上游和下游机制。以下三个目标将解决我们的核心假设,即Nemo相扑在IR介导的NF-kB激活中发挥关键的生理作用,从而调节体内的辐射敏感性:目的1:确定Nemo相扑在体内调节辐射敏感性中的作用。目的2:揭示NEMO锌指在促进NEMO相扑甲基化中的上游作用。目的3.阐明SUMO-1对NEMO功能的特异性下游调控。我们认为,拟议的研究之所以重要,主要有两个原因。首先,所描述的研究将揭示响应DNA损伤刺激的新的核因子-kB信号转导机制。其次,了解DNA损伤剂激活核因子-kB的机制可能有助于识别新的药物靶点,以改进目前的癌症治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHIGEKI MIYAMOTO其他文献
SHIGEKI MIYAMOTO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHIGEKI MIYAMOTO', 18)}}的其他基金
Impact of Host NF-kB Signaling in Radiation Therapy
宿主 NF-kB 信号传导在放射治疗中的影响
- 批准号:
10434953 - 财政年份:2021
- 资助金额:
$ 2.86万 - 项目类别:
Impact of Host NF-kB Signaling in Radiation Therapy
宿主 NF-kB 信号传导在放射治疗中的影响
- 批准号:
10297956 - 财政年份:2021
- 资助金额:
$ 2.86万 - 项目类别:
Impact of Host NF-kB Signaling in Radiation Therapy
宿主 NF-kB 信号传导在放射治疗中的影响
- 批准号:
10665545 - 财政年份:2021
- 资助金额:
$ 2.86万 - 项目类别:
New Multi-Drug Resistance Mechanism in Multiple Myeloma
多发性骨髓瘤多重耐药新机制
- 批准号:
10439626 - 财政年份:2020
- 资助金额:
$ 2.86万 - 项目类别:
New Multi-Drug Resistance Mechanism in Multiple Myeloma
多发性骨髓瘤多重耐药新机制
- 批准号:
10626002 - 财政年份:2020
- 资助金额:
$ 2.86万 - 项目类别:
New Multi-Drug Resistance Mechanism in Multiple Myeloma
多发性骨髓瘤多重耐药新机制
- 批准号:
10029257 - 财政年份:2020
- 资助金额:
$ 2.86万 - 项目类别:
New Multi-Drug Resistance Mechanism in Multiple Myeloma
多发性骨髓瘤多重耐药新机制
- 批准号:
10187534 - 财政年份:2020
- 资助金额:
$ 2.86万 - 项目类别:
Regulation of NF-kappaB by Small Ubiquitin-Like Modifiers
小泛素样修饰剂对 NF-kappaB 的调节
- 批准号:
7986606 - 财政年份:2010
- 资助金额:
$ 2.86万 - 项目类别:
Regulation of NF-kappaB by Small Ubiquitin-Like Modifiers
小泛素样修饰剂对 NF-kappaB 的调节
- 批准号:
8098970 - 财政年份:2010
- 资助金额:
$ 2.86万 - 项目类别:
Regulation of NF-kappaB by Small Ubiquitin-Like Modifiers
小泛素样修饰剂对 NF-kappaB 的调节
- 批准号:
8505491 - 财政年份:2010
- 资助金额:
$ 2.86万 - 项目类别:
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 2.86万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 2.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 2.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 2.86万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 2.86万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 2.86万 - 项目类别: